These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
463 related articles for article (PubMed ID: 27259276)
1. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Barreto R; Waning DL; Gao H; Liu Y; Zimmers TA; Bonetto A Oncotarget; 2016 Jul; 7(28):43442-43460. PubMed ID: 27259276 [TBL] [Abstract][Full Text] [Related]
2. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Barreto R; Kitase Y; Matsumoto T; Pin F; Colston KC; Couch KE; O'Connell TM; Couch ME; Bonewald LF; Bonetto A Sci Rep; 2017 Oct; 7(1):14470. PubMed ID: 29089584 [TBL] [Abstract][Full Text] [Related]
3. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. Pin F; Barreto R; Couch ME; Bonetto A; O'Connell TM J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):140-154. PubMed ID: 30680954 [TBL] [Abstract][Full Text] [Related]
5. Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repression. Yang W; Chen Y; Zhang Y; Wang X; Yang N; Zhu D Cancer Res; 2006 Feb; 66(3):1320-6. PubMed ID: 16452185 [TBL] [Abstract][Full Text] [Related]
6. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. Hulmi JJ; Nissinen TA; Räsänen M; Degerman J; Lautaoja JH; Hemanthakumar KA; Backman JT; Ritvos O; Silvennoinen M; Kivelä R J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):417-432. PubMed ID: 29230965 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies. Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586 [TBL] [Abstract][Full Text] [Related]
9. Osteocalcin Induces Proliferation via Positive Activation of the PI3K/Akt, P38 MAPK Pathways and Promotes Differentiation Through Activation of the GPRC6A-ERK1/2 Pathway in C2C12 Myoblast Cells. Liu S; Gao F; Wen L; Ouyang M; Wang Y; Wang Q; Luo L; Jian Z Cell Physiol Biochem; 2017; 43(3):1100-1112. PubMed ID: 28977794 [TBL] [Abstract][Full Text] [Related]
10. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136 [TBL] [Abstract][Full Text] [Related]
11. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643 [TBL] [Abstract][Full Text] [Related]
12. Myostatin is a novel tumoral factor that induces cancer cachexia. Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320 [TBL] [Abstract][Full Text] [Related]
13. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691 [TBL] [Abstract][Full Text] [Related]
14. [Safety and efficacy of FOLFOX and FOLFIRI in elderly patients with colorectal cancer]. Mishima H; Ikenaga M; Yasui M Nihon Rinsho; 2011 Apr; 69 Suppl 3():554-8. PubMed ID: 22214022 [No Abstract] [Full Text] [Related]
15. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). Hebbar M; Tournigand C; Lledo G; Mabro M; André T; Louvet C; Aparicio T; Flesch M; Varette C; de Gramont A; Cancer Invest; 2006 Mar; 24(2):154-9. PubMed ID: 16537184 [TBL] [Abstract][Full Text] [Related]
17. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer. Hsu HC; Chou WC; Shen WC; Wu CE; Chen JS; Liau CT; Lin YC; Yang TS Anticancer Res; 2013 Aug; 33(8):3317-25. PubMed ID: 23898098 [TBL] [Abstract][Full Text] [Related]